Westlake Medical Center Performed First Urocross Procedure
The Austin hospital marks the start of a controlled U.S. commercial release for the prostatic implant system.
Updated on Oct. 14, 2026 in Healthcare
Live Poll
Would you prefer a removable medical implant over a permanent one for a chronic condition?
The Hospital at Westlake Medical Center performed the first commercial procedure using the Urocross Expander System. This new device provides a temporary, non-permanent solution for men suffering from lower urinary tract symptoms.
Why it matters
The system offers an alternative for treating benign prostatic hyperplasia without the need for permanent foreign implants. This initial Austin procedure kicks off a controlled rollout across the United States.
Clinical study participants reported a 49% improvement in prostate symptom scores 12 months after receiving the implant. The system, which requires a non-permanent device, is retrieved six months after the initial procedure.
The players
Tyler McClintock
The physician who performed the first commercial Urocross Expander System procedure.
Prodeon Medical
The medical company that developed the Urocross Expander System.
The Hospital at Westlake Medical Center
The Austin hospital where the first commercial medical procedure took place.
The details
Physician Tyler McClintock performed the procedure at The Hospital at Westlake Medical Center by placing the implant through a flexible cystoscope to remodel the obstructed prostatic urethra. The Urocross Expander System remains in place for six months before removal. Prodeon Medical is now managing a controlled commercial release focused on providing physician training and ongoing clinical support.
Timeline
October 14, 2026: The first commercial procedure was performed in Austin.
The Texas Context
The procedure marks the transition of the Urocross Expander System from the Expander-2 clinical trial into the commercial market. This rollout follows the successful 240-patient study conducted across 23 sites in the U.S. and Canada.
Local patients with benign prostatic hyperplasia may now have access to this non-permanent treatment option as Prodeon Medical expands physician training. Residents should consult with their urologist to determine if this new procedure is suitable for their specific health needs.
The takeaway
The Urocross system uses a non-permanent implant to address prostatic obstruction for a six-month duration. Patients interested in this treatment should monitor upcoming announcements from local medical centers regarding the availability of physician-trained practitioners.
Further reading
You can follow more developments in local medical technology in our Healthcare section.
Live Poll
Would you prefer a removable medical implant over a permanent one for a chronic condition?
